Radiation before surgery for a single liver tumor
Part of Cancer, Digestive system clinical trials.
This early feasibility study tests a radiation plan given before surgery for hepatocellular carcinoma (a type of liver cancer) to see if it’s safe and doable. It may help shrink or control the tumor before an operation that aims to fully remove it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your liver cancer diagnosis is confirmed by biopsy (or meets accepted liver-cancer guideline criteria).
- You have one tumor nodule, with the largest diameter between 3 and 8 cm.
- You are planned to have curative surgery (an operation intended to fully remove the tumor), without needing a pre-surgery procedure to open up the portal vein.
- Your overall ability to do daily activities is not more than limited (performance status 2 or less).
- Your liver function is good enough for treatment (not Child-Pugh B or C decompensated cirrhosis).
- You have no tumor in the portal vein or spread outside the liver, and you have not had anti-cancer treatment in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving focused radiation therapy (SBRT) after liver surgery helps lower the chance of cancer coming back. It is for people whose surgery left a very small safety margin around the tumor.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
This study compares a standard radiation dose plan versus a plan that adjusts the dose based on how the tumor responds to radiation-related measurements. It aims to improve how well stereotactic body radiation therapy (SBRT) treats liver cancer while keeping side effects manageable.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.